Exelixis | EXEL - Sales Revenues


Exelixis reported $628.69M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 307.96M 39.9M Jun/2026
Agios Pharmaceuticals USD 44.74M 25.94M Jun/2026
Akebia Therapeutics USD 57.62M 1.14M Dec/2025
Amgen USD 10.1B 1.48B Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bayer EUR 10.87B 2.54B Jun/2026
BioMarin Pharmaceutical USD 990M 224M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Cytokinetics USD 28.6M 9.25M Jun/2026
Eisai JPY 234.33B 28.9B Jun/2026
Eli Lilly USD 22.97B 3.17B Jun/2026
Exelixis USD 628.69M 17.89M Jun/2026
Genmab DKK 1.06B 36M Dec/2025
Glaxosmithkline GBP 10.09B 1.37B Mar/2026
Incyte USD 1.67B 400M Jun/2026
Ionis Pharmaceuticals USD 268M 22M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.6B 310M Jun/2026
Moderna USD 100M 289M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Pfizer USD 15.03B 530M Jun/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Sanofi EUR 12.14B 65M Mar/2026
Takeda JPY 1.22T 130B Jun/2026
Ultragenyx Pharmaceutical USD 214M 78M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026